Lengthy-term follow-up of the BFR14 trial confirmed that Gleevec (imatinib) stays efficient in superior gastrointestinal stromal tumors (GIST), with sufferers reaching full response or full tumor removing dwelling twice as lengthy on common, based on findings introduced on the 2025 European Society of Medical Oncology Congress (ESMO).
At a median follow-up of 219 months, 434 sufferers had a median general survival of 75.3 months, with 10-, 15- and 20-year survival charges of 33.9%, 19.8% and 13.1%. Feminine intercourse, gastric tumor location, smaller main tumors, and KIT exon 11 mutations had been related to longer survival. Surgical resection of metastases with R0 margins roughly doubled median survival, and full responses correlated with extended outcomes. Sufferers enrolled within the second half of the research lived longer than these within the first half (86.1 months versus 60.6 months), and youthful females had a median survival of 100.6 months versus 64.6 months for males.
Speedy illness development was noticed within the remedy interruption arms, however all sufferers re-responded to Gleevec rechallenge. Interruption at three and 5 years was related to the next threat of creating resistance.
Glossary
Full response (CR): disappearance of all detectable tumor from the physique after remedy.
Partial response (PR): shrinkage of tumor with out full disappearance.
Secure illness (SD): most cancers that’s neither shrinking nor rising after remedy.
Progressive illness (PD): most cancers that continues to develop or unfold regardless of remedy.
R0 resection: surgical removing of all seen tumor with clear margins.
R1 resection: surgical removing of tumor with microscopic residual most cancers remaining.
R2 resection: surgical removing of tumor with seen residual most cancers remaining.
Total survival (OS): time from remedy begin or prognosis till dying from any trigger.
Development-free survival (PFS): time throughout and after remedy {that a} affected person lives with out most cancers rising or spreading.
L0: absence of detectable tumor in any respect websites after remedy.
“This replace of the BFR14 research supplies vital perception into the very long-term impacts of superior GIST sufferers handled within the early Gleevec space,” Dr. Quentin Devin, Lyon, France, mentioned through the presentation. “These findings spotlight the significance of striving for L0 and full response to maximise long-term survival in metastatic GIST. Predictive instruments developed from this research would possibly assist determine long-term survivors earlier. Additional analysis ought to increase on these findings with a concentrate on the present inhabitants and integration of newer therapeutic brokers.”
Predictors for reaching a whole response through the trial included smaller tumors, the presence of liver-only metastases, and KIT exon 11 mutations. These elements had been important each for sufferers receiving Gleevec with surgical procedure and for these handled with Gleevec alone. Age at Gleevec initiation was additionally recognized as a predictor for 15-year survival.
Total survival was additionally analyzed based on response to Gleevec and surgical intervention. Sufferers had been grouped as full response (CR) with Gleevec solely, CR with Gleevec and surgical procedure, partial response (PR) with Gleevec with or with out surgical procedure, secure illness (SD) after Gleevec, progressive illness (PD) as greatest response, and never evaluable. OS was longer in sufferers reaching CR no matter remedy modality. Evaluation by surgical standing — no surgical procedure, R0 (full resection), R1 (microscopic residual), R2 (macroscopic residual), and unknown — confirmed that R0 resection was related to improved survival.
What’s the Examine Design of BFR14?
The BFR14 research, initiated in 2002, is a multicenter, randomized section 3 medical trial that enrolled 434 sufferers with superior or unresectable gastrointestinal stromal tumors handled with Gleevec. The trial’s design in contrast Gleevec interruption to its continuation at one, three and 5 years.
Sufferers with GIST who had been progression-free after three years of Gleevec 400 milligrams per day had been randomly assigned to proceed or interrupt Gleevec. Randomization was carried out centrally and independently utilizing computer-generated permuted blocks of two and 4 sufferers, stratified by taking part middle and presence or absence of residual illness on CT. The first finish level was progression-free survival. An interim evaluation was deliberate after the primary 50 sufferers had been randomly assigned. Analyses had been carried out based on the intention-to-treat precept, together with all sufferers as assigned.
GIST was the primary stable tumor through which kinase inhibitors demonstrated a survival profit within the metastatic setting, based on research authors. Gleevec rapidly turned the usual first-line remedy for superior GIST with Gleevec-sensitive mutations, although early research reported a median general survival of round 50 months. The very long-term impacts of Gleevec in superior GIST remained unclear.
References
- “Twenty-12 months Survival of Superior Gastrointestinal Stromal Tumors Handled with Gleevec” by Dr. Devin, et al., ESMO Congress 2025.
- “Discontinuation of Gleevec in Sufferers With Superior Gastrointestinal Stromal Tumors After 3 Years of Therapy” by Dr. Le Cesne, et al., Lancet Oncology.
For extra information on most cancers updates, analysis and schooling,
